Oncolytics Biotech Inc., a development stage company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. REOLYSIN The company’s potential product for human use, REOLYSIN, is developed from the reovirus. This virus has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway. The company’s clinical program includes clinical trials which it sponsors directly along with third party clinical trials. In 2014, the U.S. National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) and the National Cancer Institute of Canada (NCIC) were sponsoring part of the company’s clinical trial program. Business Strategy The company’s business strategy is to develop and market REOLYSIN in an effective and timely manner. It intends to achieve business strategy by focusing on these key areas: develop REOLYSIN by continuing to progress the product through clinical trial program assessing the safety and efficacy in human subjects; establish collaborations with experts to assist with scientific and clinical developments of this new potential pharmaceutical product; implement strategic alliances with selected pharmaceutical and biotechnology companies and selected laboratories; utilize broadening patent base and collaborator network as a mechanism to meet strategic objectives; and develop relationships with companies that could be instrumental in assisting the company to access other innovative therapeutics. Patents and Trade Secrets The company has approximately 400 issued patents including 56 issued U.S. patents. Regulations The company’s toll manufacturers are subject to periodic inspection by the United States Food and Drug Administration, the United States Drug Enforcement Administration (DEA), and other domestic and foreign authorities where applicable, and must comply with current Good Manufacturing Practices regulations. History Oncolytics Biotech Inc. was founded in 1998. The company was incorporated in 1998 under the Business Corporations Act (Alberta).
oncolytics biotech inc (ONCY:NASDAQ CM)
1167 Kensington Crescent, NW
Calgary, AB T2N 1X7
|No competitor information is available for ONCY.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.